Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.
Center for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Aliment Pharmacol Ther. 2019 Mar;49(5):537-545. doi: 10.1111/apt.15092. Epub 2019 Jan 9.
Outcomes after Nonvariceal upper gastrointestinal bleeding (NVUGIB) have historically focused on ulcer-related causes. Little is known regarding non-ulcer bleeding, the most common cause of NVUGIB.
To compare outcomes between ulcer- and non-ulcer-related NVUGIB and explore whether these could be explained by differences in baseline characteristics, bleeding severity or processes of care.
Analysis of 4474 patients with NVUGIB from 212 United Kingdom hospitals as part of a nationwide audit. Logistic regression models were used to adjust for baseline characteristics, bleeding severity and processes of care.
1682 patients had ulcer-related and 2792 patients had non-ulcer-related bleeding. Those with ulcer-related bleeding were older (median age 73 vs 69, P < 0.001), less likely to have been taking a PPI (18% vs 32%, P < 0.001), more likely to have been taking aspirin (40% vs 27%, P < 0.001) and present with shock (43% vs 32%, P < 0.001). Furthermore, those with ulcer-related bleeding were more likely to receive blood transfusion (66% vs 39%, P < 0.001), PPI infusion (27% vs 5%, P < 0.001) and endoscopic therapy (37% vs 8%, P < 0.001). Overall, ulcer-related bleeding had higher odds of in-hospital mortality (OR: 1.54; 95% CI: 1.21-1.96, P < 0.0001), rebleeding (OR: 2.08; 95% CI: 1.73-2.51, P < 0.0001) and need for surgical/radiologic intervention (OR: 2.64; 95% CI: 1.85-3.77, P < 0.0001). The associations disappeared after adjustment for bleeding severity, whereas adjustment for patient characteristics or process of care factors had no impact.
Patients with ulcer-related NVUGIB bleeding have worse outcomes than those with non-ulcer-related NVUGIB bleeding, which is due to more severe bleeding.
非静脉曲张性上消化道出血(NVUGIB)的预后结果一直以来都集中在与溃疡相关的病因上。对于非溃疡性出血,即 NVUGIB 最常见的病因,人们知之甚少。
比较与溃疡相关和非溃疡相关的 NVUGIB 之间的预后结果,并探讨这些结果是否可以通过基线特征、出血严重程度或治疗过程的差异来解释。
对来自英国 212 家医院的 4474 例 NVUGIB 患者进行分析,该研究为一项全国性审计的一部分。使用逻辑回归模型对基线特征、出血严重程度和治疗过程进行调整。
1682 例患者为溃疡相关出血,2792 例患者为非溃疡相关出血。与溃疡相关的出血患者年龄更大(中位数年龄 73 岁 vs 69 岁,P<0.001),接受质子泵抑制剂(PPI)治疗的可能性较低(18% vs 32%,P<0.001),更有可能服用阿司匹林(40% vs 27%,P<0.001),且更可能出现休克(43% vs 32%,P<0.001)。此外,与溃疡相关的出血患者更有可能接受输血(66% vs 39%,P<0.001)、PPI 输注(27% vs 5%,P<0.001)和内镜治疗(37% vs 8%,P<0.001)。总体而言,与溃疡相关的出血具有更高的院内死亡率(OR:1.54;95%CI:1.21-1.96,P<0.0001)、再出血(OR:2.08;95%CI:1.73-2.51,P<0.0001)和需要手术/放射介入治疗(OR:2.64;95%CI:1.85-3.77,P<0.0001)的风险。在调整出血严重程度后,这些关联消失,而调整患者特征或治疗过程因素则没有影响。
与非溃疡相关的 NVUGIB 出血相比,与溃疡相关的 NVUGIB 出血患者的预后结果更差,这是由于出血更严重所致。